EP12.01-05 Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients

B. Távara,L. López,S. Medina,M.L. Garrido,A. López,M. López,M.E. Vallejo Pascual,P. Diz Taín

Journal of Thoracic Oncology（2023）

引用 0|浏览6

暂无评分

摘要

Osimertinib, a third-generation irreversible EGFR tyrosine kinase inhibitor (TKI) effectively inhibits EGFR+, including T790M EGFR resistance. We describes real-world clinical outcomes in EGFR+ advanced NSCLC patients treated with osimertinib.

查看译文

关键词

lung cancer,egfr+,osimertinib,receptor-mutated,non-small-cell,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要